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Abstract: The blood-brain barrier (BBB) effectively prevents microtubule stabilizing drugs from 
readily entering the central nervous system (CNS).  A major limiting factor for microtubule 
stabilizing drug permeation across the BBB is the active efflux back into the circulation by the 
over-expression of the multidrug resistant gene product (MDR1) or P-glycoprotein (P-gp).   This 
study has focused on strategies to overcome P-gp-mediated efflux of taxol analogues, 
microtubule (MT) stabilizing agents that could be used to treat brain tumors and, potentially, 
neurodegenerative diseases such as Alzheimer’s disease.   However, taxol is a strong P-gp 
substrate which limits its distribution across the BBB and therapeutic potential in the CNS.  We 
have found that addition of a succinate group to the C-10 position of taxol results in an agent, 
Tx-67, with reduced interactions with P-gp and enhanced permeation across the BBB in both in 
vitro and in situ models.  Our studies demonstrate the feasibility of making small chemical 
modifications to taxol to generate analogues with reduced affinity for the P-gp but retention of 
MT-stabilizing properties, i.e., a taxane that may reach and treat therapeutic targets in the CNS.  
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Introduction 
 The delivery of therapeutic agents into the brain continues to be a challenge for the 
pharmaceutical industry.   Due to the inadequate delivery of these agents to the desired site of 
action in the brain, many neurological disorders (i.e., brain tumors, Alzheimer’s disease, and 
other brain disorders) have poor responses to drug treatment (Pardridge, 2002).  We have 
previously shown in neuronal cell cultures that the microtubule-stabilizing drug taxol protects 
neurons against amyloid peptide (Aβ) toxicity (Michaelis et al., 1998, 2002).  The potential for 
testing protective effects in vivo is severely limited by the failure of taxol and several of its 
derivatives to enter the brain.  Consequently, we have synthesized a large array of  MT-
stabilizing drugs related to taxol and tested them for potential to penetrate into the brain.  In 
this paper we discuss the strategies we have tested and the results obtained regarding brain 
permeability of one promising taxane. 
The blood-brain barrier (BBB) regulates the influx and efflux of a wide variety of 
substances and remains the major obstacle in the delivery of drugs into the central nervous 
system (CNS).  The most common mechanism for drug distribution across the BBB is by simple 
passive diffusion; however, once a drug enters the endothelial lining of the BBB by this 
mechanism, it may either undergo passive diffusion or active transport back out of the cells into 
the circulation.  First identified in tumors, the active efflux transport mechanisms are implicated 
as major factors in limiting the effective delivery of a number of drugs and drug classes across 
the BBB (Schinkel, 1999; Taylor, 2002).   The transporters responsible for the active efflux of 
drugs at the BBB include the multidrug resistant gene product 1 (MDR1) or P-glycoprotein (P-
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gp), multidrug resistance-associated proteins (MRPs), and the breast cancer resistance protein 
(BCRP).  The major efflux pump at the BBB is MDR or P-glycoprotein (Schinkel, 1999; Taylor, 
2002).   
P-glycoprotein is a member of the ATP-binding cassette (ABC) family of transport 
proteins (Gottesman et al., 1996).  This transporter is located on the blood side of the capillary 
endothelial cell and is involved in the efflux of a wide range of substrates that include 
antineoplastic agents (e.g., vincristine, vinblastine, and taxol), antiviral compounds (e.g., 
saquinavir, ritonavir, indinavir), opiates, and other therapeutic agents. Various strategies have 
been devised to circumvent the BBB in order to increase drug delivery to the CNS.  These 
strategies involve attempts to manipulate either the chemical properties of the agent, opening 
the BBB by increasing capillary endothelial permeability, or enhancing the driving force for 
transport by increasing the plasma concentration of a drug (i.e., high dose chemotherapy, intra-
arterial injection) (Taylor, 2002; Siegal and Zylber-Katz, 2002).   
 The strategy we chose to overcome the BBB efflux mechanisms was to focus on the use 
of combinatorial chemistry to manipulate chemical structure in order to reduce affinity for P-
gp.  This type of approach has been successfully used, for example, to generate molecular 
diversity in chemical structures for the development of new antibacterial agents in order to 
overcome bacterial-drug resistance (Desnottes, 1996).   The starting point for our work was to 
generate and screen newly synthesized analogues of the anticancer agent, paclitaxel or taxol, 
for taxanes that have reduced P-gp affinity relative to the parent drug.  Taxol, one of the 
leading anticancer drugs currently on the market for the treatment of ovarian and breast 
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cancer, is very effective in treating tumors but, unfortunately, is also a substrate for the P-gp 
efflux pump.  Due to interactions with P-gp at the BBB, it is almost impossible to infuse taxol 
vascularly to treat brain tumors (Cahan et al., 1994; Brouty-Boye et al., 1995; Lovich et al., 
2001; Fellner et al., 2002).  Therefore, second-generation taxanes that retain appropriate 
pharmacological activity and have reduced interactions with P-gp were generated with the 
primary objective of improving distribution across the BBB.  To characterize these new taxanes 
we have employed a combination of in vitro and in situ models of the BBB.    The goals of 
experiments described herein were to: 1) determine which newly synthesized taxanes have 
reduced P-gp interactions and improved permeability properties relative to taxol, using an in 
vitro model comprised of P-gp-expressing primary cultures of brain microvessel endotheial 
cells, and 2) determine which newly synthesized taxanes have improved permeability 
properties relative to taxol at the BBB, using an in situ rat brain perfusion model.  Taxol and the 
taxanes that were employed in the permeability assays here have previously been shown to 
retain appropriate pharmacological properties with respect to protecting neurons against Aβ-
induced toxicity (Michaelis et al., 1998; 2002). 
 
Methods 
Bovine brain microvessel endothelial cells (BBMECs) were isolated from the gray matter of 
cerebral cortices by enzymatic digestion and subsequent centrifugation, and seeded into primary culture 
as described (Audus and Borchardt, 1987; Audus et al. 1996). Uptake and transport studies were 
performed in pH 7.4 standard buffer solutions, consisting of either Hank’s balanced salt solution (HBSS) 
or phosphate buffered saline (PBS) supplemented with 0.63 mM CaCl2, 0.74 mM MgSO4, 5.3 mM 
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glucose, and 0.1 mM ascorbic acid (PBSA).  [3H] Taxol (specific activity 10.5 Ci/mmol) was obtained from 
Moravek Radiochemicals.  Dr. Gunda Georg, Medicinal Chemistry Department, University of Kansas, 
supplied the taxol and taxane analogs.  Rhodamine 123 (Rho 123) and cyclosporin A (CsA) were obtained 
from Sigma. 
Rhodamine 123 Accumulation in the Presence of Taxanes 
BBMECs were grown in 12-well plates to form confluent monolayers and used as 
described to assay for P-gp as detailed elsewhere (Rose et al., 1998).  Briefly, the fluorescent 
marker Rho 123 was dissolved in PBSA buffer to give a stock concentration of 100 μM.  The 
uptake assay was performed in 1 ml of fresh PBSA.  An aliquot of taxol or one of its analogues 
was added to each well to give a final concentration of 25 μM.  As a positive control, the P-gp 
inhibitor CsA (5 –10 μM) was used.  The negative control was rhodamine (5-10 μM) alone.  The 
cells were pre-incubated at 37 oC with taxol or an analogue for approximately 45 min.  After this 
pre-incubation period, Rho 123 was added to the cells.  After a 45-min incubation, the cells were 
washed in cold PBS and lysed in a NaOH/Triton X-100 solution.  The cell lysates were assayed 
using a fluorescence spectrophotometer.  Rho 123 was measured at excitation/emission 
wavelengths of 500 nm/535 nm, and quantified against a standard curve of Rho 123 in the 
appropriate lysing solution.  The protein content was determined using the BCA protein assay 
reagent kit and the results were expressed as total fluorescence accumulation per mg of cell 
protein. 
Transport of Taxanes across BBMEC Monolayers 
The BBMECs were grown on 0.4 μm pore polycarbonate membranes essentially as 
described (Audus and Borchardt 1987; Audus et al. (1996).  When they reached confluency, the 
cells were transferred to side-by-side diffusion chambers to characterize the transport of a small 
number of promising tritium-labeled by assessing their permeability relative to that of the 
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paracellular marker [14C]-sucrose as an index of monolayer confluency.  Bi-directional transport 
was assessed for each of the radiolabeled compounds to determine if polarized transport was 
observed.  All of the studies were performed in 3 ml of stirred PBSA in each donor and receiver 
chamber at 37oC.  The cells were allowed to equilibrate in PBSA for 30 minutes prior to the 
experiment.  At each time point, 100 μl of sample were taken from the receiver compartment and 
immediately replaced with an equal volume of PBSA.     Apparent permeability coefficients 
(Papp) were calculated according to the following equation: 
Papp = (V/ACo) * (dC/dt) 
Where V= volume of the receiver chamber (3.0 cm3), A = area of the filter (0.636 cm2), 
Co = initial donor concentration and (dC/dt) = flux of the test agent.   
In Situ Rat Brain Perfusion of Taxanes 
 The in situ rat brain perfusion technique described by Smith (1996), was employed to determine 
the BBB permeability of taxol and the taxane analog Tx-67.  Adult male Sprague-Dawley rats (350-400g) 
were anesthetized with a mixture containing: 1.5 ml/kg of solution consisting of 37.5 mg/ml ketamine, 
1.9 mg/ml xylazine, and 0.37 mg/ml acepromazine. The rat brain was then directly perfused through the 
left carotid artery with a buffered physiologic saline containing a tracer (sucrose) as a vascular marker 
and the sample ([3H]-taxol or [14C]-Tx-67) for time periods of 30, 60, or 120 seconds.  The perfusion 
solution was changed to tracer-free fluid for 30 sec to clear the labeled compound from the cerebral 
vessels.  After the perfusion, the rat was decapitated and the brain removed for sampling of various 
regions.  The brain tissue was digested in Solvable for 24 hrs and the radioactivity quantified via liquid 
scintillation spectrometry.  The capillary permeability-surface area product (PA) (ml/s/g) was calculated 
for both taxol and Tx-67 by the following equation: 
PA = -F Ln [1-C*br (T)/ F T C*pf] 
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Where F is the regional cerebral blood flow (ml/s/g); C*br represents the concentration of tracer in the 
brain parenchyma (dpm/g); C*pf is the concentration in the perfusion fluid (dpm/ml); and T is the total 
perfusion time. 
 
 Results 
 Rhodamine 123 accumulation was assessed in the presence of taxol and the new 
analogues of taxol.  Although it is an indirect assay, our studies revealed that some of the 
synthetic taxanes appeared to have reduced interactions with P-gp (i.e., no increase in Rho 123 
accumulation in the presence of the analogues). Taxol, a known substrate for P-gp, increased 
rhodamine uptake by 2-2.5 fold in the BBMECs.   Rhodamine uptake in the presence of taxol 
was very similar to that observed in the presence of the positive control, CsA (5 µM), a known 
P-gp inhibitor.  Accordingly, from the Rho 123 screening of numerous taxanes in multi-well dish 
formats, we obtained a rather quick analysis of which taxanes were poor substrates efflux by P-
gp.  One of the taxanes that had no apparent interactions with P-glycoprotein, i.e., no effect on 
Rho 123 uptake by BBMECs, was designated ‘Tx-67’, a compound in which a succinate group 
was added at the C-10 position of taxol. 
 We next assessed the actual permeability properties of Tx-67 relative to taxol.  
Given that the BBMECs have an apical and a basolateral surface when grown on polycarbonate 
membranes, our permeation studies included an assessment of whether the permeation was 
polarized or asymmetric in nature.  We used radiolabeled taxol and Tx-67 for these experiments 
to provide sensitivity in the nM concentration range.  The apparent permeability coefficient for 
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taxol was greater in the basolateral (b) to apical (a) direction (i.e., b---a  > a---b).  We also 
observed that the analogue, Tx-67, had enhanced permeation compared to that of taxol.  The 
apparent permeability coefficient of Tx-67 at any concentration (low or high) was substantially 
greater than the Papp for taxol at the highest concentration used (25 μM).   Moreover, the 
permeation of Tx-67 was asymmetric, but greater in the apical to basolateral direction which 
suggests greater blood to brain permeation for the new taxane.   Figure 1 shows typical results 
for taxol and Tx-67 permeability at 20 nM, a concentration at which the BBMEC P-gp is not 
saturated, and at 10 µM, a concentration at which the transporter is presumed to be saturated and 
thus the permeability of the monolayers to both agents significantly increased.   It is important to 
note that BBMEC monolayer permeability to radiolabeled sucrose (i.e., a marker for integrity 
and background monolayer “leakage”) was not altered by exposure to either taxol or Tx-67 under 
the conditions of these experiments. 
 In the in situ perfusion experiments with [14C] Tx-67 and [3H] taxol, we observed a 
substantially greater apparent permeability coefficient for Tx-67 relative to taxol.   It appears 
that the taxol is not retained in the rat brain tissue as only minimal amounts (2.5% or less of 
total control) were detectable in the brain at 120 sec.  Approximately 6 to 8% of the total Tx-67 
was detectable after 60 sec of perfusion.  Table 1 lists the Papps determined for Tx-67 and taxol 
at each perfusion time. 
 
Table 1. The Apparent Permeability Coefficients for [14C] Tx-67 and [3H] Taxol in the in situ rat brain 
perfusion.  Time points were for: 30, 60, and 120 seconds (each time point was determined in duplicate 
experiments). 
               Papp x 107 cm/sec 
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Compound 30 sec 60 sec 120 sec 
[14C] Tx-67 8.47 13.71 10.75 
[3H] Taxol 0.845 1.700 1.574 
 
 
Discussion 
 The initial Rho 123 screening of newly synthesized taxanes showed that some structural 
modifications to taxol generated through combinatorial chemistry approaches lead to compounds that 
appear to be less avid substrates for P-gp than the parent taxol.  Clearly taxol competes with Rho 123 for 
P-gp, resulting in increased fluorescence using this screening technique.  On the other hand, Tx-67 
appeared to interact with P-gp to a significantly lesser degree in the same assay.  Despite the addition of 
the succinyl group, Tx-67 retained its MT-stabilizing properties and its effectiveness in protecting 
neurons against Aβ-induced toxicity as reported earlier (Michaelis et al., 2002).  These findings are 
consistent with studies in other laboratories that show second-generation taxanes have reduced 
interactions with P-gp and yet still exhibit potent anticancer activity (Ojima et al., 1996; Ojima and 
Slater, 1997).   
We also determined that the transport of taxol across BBMEC monolayers was asymmetric and 
supports previous data that the P-gp is localized on the apical side of the brain (Cordon-Cardo et al., 
1989; Tsuji et al., 1992).  However, the new taxane, Tx-67, although asymmetric in permeation across 
the monolayers, showed a much higher permeability favoring what would be blood to brain distribution 
in this model.   The in situ rat brain perfusion data correlated well with our in vitro permeability data, 
showing that Tx-67 permeation across the BBB was in fact substantially greater than the permeation of 
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Taxol into rat brains.  Our taxol data were comparable to perfusion data for other anticancer drugs such 
as vincristine and vinblastine (Greig et al., 1990). 
 We have demonstrated that the use of combinatorial chemistry led to synthesis of new taxanes 
with reduced interactions with P-glycoprotein.   We have also been able to demonstrate that one of the 
newly synthesized analogs, Tx-67, appears to cross the BBB both in vitro and in situ more readily than 
the parent drug.  The Tx-67 permeation studies support our hypothesis that chemical modification of 
taxol does enhance its permeability into the brain.  In addition, the work is consistent with literature 
observations where small changes in chemical structures can alter interactions with P-glycoprotein at 
the BBB and thereby influence the distribution of the agents into the CNS (Mann et al., 1997).  The most 
significant aspect of these results is that we now have an agent with MT-stabilizing activity and strong 
neuroprotective actions against Aβ in primary neuronal cultures that can be tested in vivo.  Studies are 
being undertaken to characterize the pharmacokinetic and pharmacodynamic properties of Tx-67 in 
mice.  This is being done in anticipation of testing its therapeutic potential in animal models of both 
neurodegenerative diseases and brain tumors.   
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Figure Legends: 
 
Figure 1.  Concentration-dependence of apparent permeability coefficients (Papp) for taxol and Tx-67 
permeation across primary cultures of BBMEC monolayers at 37°C.    The data summarized are the 
Papps for taxane permeation from the apical (blood) to basolateral (brain) side of the monolayers.   The 
data points are means ± standard deviations for at least four different monolayers.   
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